Israel’s Teva Pharmaceutical Industries Ltd. has reported that the FDA has granted final approval of the abbreviated new drug application for its venlafaxine hydrochloride tablets, in 25mg, 37.5mg, 50mg, 75mg and 100mg doses.

The tablets are the generic equivalent of Wyeth Pharmaceuticals’ Effexor, used to treat major depressive disorder (MDD).

The product is to begin shipping immediately, according to Teva. The brand product has annual sales of around $152 million, the company noted.

Comments are closed.